Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential anticoagulant prophylaxis in hospitalized traumatic fracture patients
ChiCTR2100049891Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Aug 2021
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of fondaparinux in venous thromboembolism (VTE) (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Incidence of venous thromboembolism events. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
fondaparinux
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on ChiCTR2100049891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049891.